|By Marketwired .||
|May 16, 2014 08:05 AM EDT||
LONGMONT, CO -- (Marketwired) -- 05/16/14 -- MediJane Holdings Inc. (OTCQB: MJMD) ("MediJane" or "MJMD" or the "Company") today reported that further to its recently launched California expansion plan, the Company is pleased to announce that it has successfully concluded a recruitment process and has appointed Franceen Reeves as MediJane's new Head of Sales for the state of California.
Ms. Reeves graduated from Texas Christian University with a Bachelor of Science in Nursing (BSN). Upon graduation, she was commissioned into the United States Air Force as a 2nd Lieutenant and began working as a Security Forces Officer. As acting Officer In-Charge of Training & Resources for the 72nd Security Forces Squadron, she was responsible for a team of 36 personnel, assets worth over $15.5M (including 25 vehicles, 1054 weapons in the armory, and managed a budget of $1.8M. Ms. Reeves was the lead training coordinator for over 430 base-wide representatives on anti-terrorism training measures post 9-11. She was also influential in attaining $3.4M anti-terrorism funding from higher headquarters for the mitigation of Tinker Air Force Base's internal and external vulnerabilities.
Ms. Reeves decided to pursue her passion and cross-train into healthcare for her last two years of military service. She was moved to Andrews Air Force Base for her remaining time in the force. Ms. Reeves acted as In-House Supervisor for the Multi-Specialty Unit at Malcolm Grow Hospital and was then promoted to the rank of Captain.
Following her service in the U.S. military, Ms. Reeves worked at Kindred Healthcare for a few years. Although she enjoyed the training she received from a medical and clinical standpoint, she wanted to move toward the business side of healthcare and decided to pursue the medical device industry.
After Kindred Healthcare, she went to work for Boston Scientific as a Clinical Specialist in the Neuromodulation Division. Her role at Boston Scientific was educating anesthesiologists and orthopedic surgeons on the use of an implantable pain-relief device. She programmed the device intra and post operatively, running over 45 cases in the OR. She also managed the largest account in the territory, which generated $1M in revenue a year.
She has spent the last 5 years within the Medical Device Industry, which included her most recent clinical sales position working as a contractor for Gambro. In this position, she worked with cardiologists, nurse managers, medical directors, and CNO's. Gambro AB, a global leader in the development, manufacturing, and supply of products and therapies for kidney and liver dialysis, myeloma kidney therapy, and other extracorporeal therapies for chronic and acute patients, was acquired by Baxter International Inc. in 2012.
"Ms. Reeves' vast clinical and practical medical experience, personnel & resource management, and hands-on sales skills makes her an ideal candidate for the position of MediJane Head of Sales for California," commented Ronald Lusk, CEO of MediJane Holdings Inc. "Her being a proud patriot and military veteran also assisted me in the decision to add Franceen to the MediJane team."
About MediJane Holdings Inc. (MJMD)
MediJane Holdings Inc. (MJMD) is in the business of marketing and distributing products within the medical marijuana industry, including transdermal patches, capsules, sublingual sprays, and other medical delivery systems as part of its strategic alliances with Phoenix Bio Pharmaceuticals (www.phoenixbiopharmaceuticals.com). With sales offices opening in California and Colorado, and a planned expansion into a national footprint, MediJane products are designed to give doctors the ability to provide patients accurate and effective doses of cannabinoids to manage and treat pain and other specific illnesses. MediJane's lead products, the innovative non-drowsy "Daytime Pain plus CBD" oral capsule and the Canna-Mist cannabinoid spray, have been formulated for the treatment of inflammation and chronic, neuropathic, arthritic, and back pain. These smokeless alternatives provide accurate dosages and are part of MediJane's initial launch into the chronic pain management market, which is estimated at over $45 billion annually in North America. Any and all medically oriented statements have not been evaluated by the Food and Drug Administration.
For more information, visit www.medijane.co
Disclaimer/Safe Harbor: Some information in this MediJane Holdings Inc. (MJMD) press release constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements. The words "plan", "forecast", "anticipates", "estimate", "project", "intend", "expect", "should", "believe," and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to, known and unknown risks, uncertainties and other factors which could cause MJMD's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to MJMD herein are expressly qualified in their entirety by the above-mentioned cautionary statement. MJMD disclaims any obligation to update forward-looking statements contained in this press release, except as may be required by law.